Friday, May 9, 2025
5/9/2025
CUREIT: Curing the Uncurable via RNA-Encoded Immunogene Tuning - More than 25 million Americans currently live with autoimmune disease, and almost two million are projected to be diagnosed with cancer in 2023. Immune dysregulation is an underlying component of not only cancer and autoimmune diseases, but also infectious diseases, transplant rejection, and other common medical conditions. Current methods of immune modulation used to treat and mitigate these conditions are often expensive or not completely effective. Curing the Uncurable via RNA-Encoded Immunogene Tuning (CUREIT) aims to address immune dysregulation by directly programming immune cell function. Advances in gene-encoded technology will be leveraged to develop a platform capability able to both enhance protective immune responses as well as modulate insufficient or ineffective immune profiles. CUREIT seeks to develop a disease-agnostic toolbox of methods and technologies, including the in vivo delivery of mRNA-based drugs, cell targeting lipid nanoparticles, and ex vivo modulation of immune cells. This technology has the potential to make significant advancements towards managing or eliminating many diseases and conditions affecting all ages and demographics, including diseases which are currently untreatable.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).